CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation

Nature Medicine

Volumn 9, Issue 9, 2003, Pages 1144-1150

  Edinger, Matthias ^a,b   Hoffmann, Petra ^a,b   Ermann, Joerg ^a   Drago, Kathryn ^a   Garrison Fathman, C ^a   Strober, Samuel ^a   Negrin, Robert S ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; INTERLEUKIN 2 RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PERFORIN;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; EFFECTOR CELL; FEMALE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; LEUKEMIA; LYMPHOCYTE PROLIFERATION; LYMPHOMA; LYSIS; MOUSE; NONHUMAN; OUTCOMES RESEARCH; PRIORITY JOURNAL; T LYMPHOCYTE;

ANIMALS; BONE MARROW TRANSPLANTATION; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; INTERFERON TYPE II; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LEUKEMIA; LYMPHOMA; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, MUTANT STRAINS; PORE FORMING CYTOTOXIC PROTEINS; RECEPTORS, INTERLEUKIN; RECEPTORS, INTERLEUKIN-2; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

ANIMALIA;

EID: 0141461418     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm915     Document Type: Article

References (44)

1. Martin, P.J. et al. Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts. Blood 66, 664-672 (1985).
2. Curtis, R.E. et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 94, 2208-2216 (1999).
3. Kolb, H.J. et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76, 2462-2465 (1990).
4. Molldrem, J.J. et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat. Med. 6, 1018-1023 (2000).
5. Horowitz, M.M. et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75, 555-562 (1990).
6. Truitt, R.L. & Johnson, B.D. Principles of graft-vs.-leukemia reactivity. Biol. Blood Marrow Transplant. 1, 61-68 (1995).
7. Weiden, P.L. et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N. Engl. J. Med. 300, 1068-1073 (1979).
8. Ferrara, J., Deeg, H.J. & Burakoff, S.J. Graft-vs.-Host Disease (Marcel Dekker, New York, 1997).
9. Ho, V.T. & Soiffer, R.J. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood 98, 3192-3204 (2001).
10. Siadak, M. & Sullivan, K.M. The management of chronic graft-versus-host disease. Blood Rev. 8, 154-160 (1994).
11. Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M. & Toda, M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155, 1151-1164 (1995).
12. + suppressor T cells. J. Exp. Med. 193,F41-46 (2001).
13. Shevach, E.M., Thornton, A. & Suri-Payer, E. T lymphocyte-mediated control of autoimmunity. Novartis Found. Symp. 215, 200-211, 211-230 (1998).
14. Shevach, E.M. Regulatory T cells in autoimmmunity. Annu. Rev. Immunol. 18, 423-449 (2000).
15. + immunoregulatory T cells that control autoimmune diabetes. Immunity 12, 431-440 (2000).
16. + T cells regulate the expansion of peripheral CD4 T cells through the production of IL-10. J. Immunol. 166, 3008-3018 (2001).
17. + T cells. Proc. Natl. Acad. Sci. USA 99, 8832-8837 (2002).
18. + regulatory T cells prevent graft rejection: CTLA-4- and IL-10-dependent immunoregulation of alloresponses. J. Immunol. 168, 1080-1086 (2002).
19. + regulatory cells in acquired MHC tolerance. Immunol. Rev. 182, 99-112 (2001).
20. + immune regulatory cells inhibits graft-versus-host disease lethality. Blood 99, 3493-3499 (2002).
21. + immunoregulatory T cells: new therapeutics for graft-versus-host disease. J. Exp. Med. 196, 401-406 (2002).
22. + regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J. Exp. Med. 196, 389-399 (2002).
23. Hakim, F.T.M. & Crystal, L. The immune system: effector and target of graft-versus-host disease, in Graft-vs-Host Disease (eds. Ferrara, J.L.M., Deeg, H.J. & Burakoff, S.J.) 257-289 (Marcel Dekker Inc., New York, 1997).
24. Sprent, J., Schaefer, M., Lo, D. & Korngold, R. Properties of purified T cell subsets, II. In vivo responses to class I vs. class II H-2 differences. J. Exp. Med. 163, 998-1011 (1986).
25. Contag, P.R., Olomu, I.N., Stevenson, D.K. & Contag, C.H. Bioluminescent indicators in living mammals. Nat. Med. 4, 245-247 (1998).
26. Contag, C.H., Jenkins, D., Contag, P.R. & Negrin, R.S. Use of reporter genes for optical measurements of neoplastic disease in vivo. Neoplasia 2, 41-52 (2000).
27. Costa, G.L. et al. Adoptive immunotherapy of experimental autoimmune encephalomyelitis via T cell delivery of the IL-12 p40 subunit. J. Immunol. 167, 2379-2387 (2001).
28. Sweeney, T.J. et al. Visualizing the kinetics of tumor-cell clearance in living animals. Proc. Natl. Acad. Sci. USA 96, 12044-12049 (1999).
29. Edinger, M. et al. Noninvasive assessment of tumor cell proliferation in animal models. Neoplasia 1, 303-310 (1999).
30. Edinger, M. et al. Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging. Blood 101, 640-648 (2003).
31. Schmaltz, C. et al. Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect. Blood 97, 2886-2895 (2001).
32. Warnke, R.A. et al. The pathology and homing of a transplantable murine B cell leukemia (BCL1). J. Immunol. 123, 1181-1188 (1979).
33. Zeng, D. et al. Unique patterns of surface receptors, cytokine secretion, and immune functions distinguish T cells in the bone marrow from those in the periphery: impact on allogeneic bone marrow transplantation. Blood 99, 1449-1457 (2002).
34. Ferrara, J.L., Levy, R. & Chao, N.J. Pathophysiologic mechanisms of acute graft-vs.-host disease. Biol. Blood Marrow Transplant. 5, 347-356 (1999).
35. Krenger, W., Hill, G.R. & Ferrara, J.L. Cytokine cascades in acute graft-versus-host disease. Transplantation 64, 553-558 (1997).
36. + immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J. Exp. Med. 188, 287-296 (1998).
37. + T cells facilitate the induction of T cell anergy. J. Immunol. 167, 4271-4275 (2001).
38. + immunoregulatory cells. J. Immunol. 167, 1137-1140 (2001).
39. + human thymocytes. J. Exp. Med. 196, 379-387 (2002).
40. Teshima, T. et al. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat. Med. 8, 575-581 (2002).
41. + T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. J. Immunol. 160, 1212-1218 (1998).
42. + regulatory, contact-dependent T cells induce interleukin 10-producing, contact-independent type 1-like regulatory T cells. J. Exp. Med. 196, 247-253 (2002).
43. Morrison, S.J. & Weissman, I.L. The long-term repopulating subset of hematopoietic stem cells is deterministic and isolatable by phenotype. Immunity 1, 661-673 (1994).
44. Ailles, L. et al. Molecular evidence of lentiviral vector-mediated gene transfer into human self-renewing, multi-potent, long-term NOD/SCID repopulating hematopoietic cells. Mol. Ther. 6, 615-626 (2002).